Form 8-K - Current report:
SEC Accession No. 0001144204-18-006087
Filing Date
2018-02-07
Accepted
2018-02-06 20:05:31
Documents
8
Period of Report
2018-02-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tv484840_8k.htm 8-K 18843
2 EXHIBIT 10.1 tv484840_ex10-1.htm EX-10.1 246521
3 EXHIBIT 99.1 tv484840_ex99-1.htm EX-99.1 7424
4 GRAPHIC image_001.jpg GRAPHIC 6203
5 GRAPHIC image_002.jpg GRAPHIC 1288
6 GRAPHIC image_003.jpg GRAPHIC 1516
7 GRAPHIC image_004.jpg GRAPHIC 2173
8 GRAPHIC image_005.jpg GRAPHIC 1661
  Complete submission text file 0001144204-18-006087.txt   292469
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-13341 | Film No.: 18579034
SIC: 2836 Biological Products, (No Diagnostic Substances)